Antiepileptics in the treatment of alcohol withdrawal and alcohol use relapse prevention

Mark A. Frye, Victor M. Karpyak, Daniel Hall-Flavin, Ihsan M. Salloum, Andrew McKeon, Doo Sup Choi

Research output: Chapter in Book/Report/Conference proceedingChapter


In the World Health Organization’s Global Burden of Disease Study (1), alcohol use disorders (abuse and dependence) ranked fifth in the undeveloped world and second in the developed world (ages 15-44 years) in disability-adjusted life years (DALYs); this measure is a composite of time lost because of premature mortality and time lived with a disability. In the United States alone, approximately 18 million people, or 7% of the population, suffer from alcohol abuse or dependence. The direct and indirect economic burden ascribed to alcohol use is estimated to be $185 billion (2). Clearly, more effective prevention and treatment of this major public health problem is needed.

Original languageEnglish (US)
Title of host publicationAntiepileptic Drugs to Treat Psychiatric Disorders
PublisherTaylor and Francis
Number of pages12
ISBN (Electronic)9780849382666
ISBN (Print)0849382599, 9780849382598
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Psychology(all)


Dive into the research topics of 'Antiepileptics in the treatment of alcohol withdrawal and alcohol use relapse prevention'. Together they form a unique fingerprint.

Cite this